| Literature DB >> 27633035 |
Ernest Cudjoe Opoku1,2, Annette Olsen3, Edmund Browne4, Abraham Hodgson1, John K Awoonor-Williams5, Lawrence Yelifari5, John Williams1, Pascal Magnussen3,6.
Abstract
BACKGROUND: The benefits of integrated control of malaria, schistosomiasis, and soil-transmitted helminth infections have not been fully explored in Ghanaian schoolchildren.Entities:
Keywords: anaemia; co-administered intermittent preventive treatment of malaria and deworming; recall; schoolchildren; sustained attention
Year: 2016 PMID: 27633035 PMCID: PMC5025525 DOI: 10.3402/gha.v9.32197
Source DB: PubMed Journal: Glob Health Action ISSN: 1654-9880 Impact factor: 2.640
Characteristics of class three schoolchildren enrolled by study arm in KNDs, Ghana, 2011
| Characteristics | Arm 1 ( | Arm 2 ( | Arm 3 ( |
|---|---|---|---|
| Sex | |||
| Boys ( | 73 (40.6) | 38 (21.1) | 56 (31.1) |
| Girls ( | 58 (34.5) | 52 (70.3) | 71 (42.3) |
| Mean age in years, (%) | |||
| 6–9 | 28 (21.4) | 26 (28.9) | 37 (29.1) |
| 10–12 | 64 (48.9) | 49 (54.4) | 70 (55.1) |
| 13–15 | 39 (29.8) | 15 (16.7) | 20 (15.7) |
| Weight (kg) | |||
| Mean/SD | 29.8/5.9 | 31.8/4.4 | 29.3/5.5 |
| Range | 20.8–43.0 | 25.7–46.4 | 17.6–50.9 |
| Height (cm) | |||
| Mean/SD | 142.6/10.9 | 141.1/6.3 | 139.6/9.5 |
| Range | 122–168 | 126–155 | 120–165 |
| Lives with at least one parent: yes | 128 (97.7) | 87 (96.7) | 124 (97.6) |
| Mother's educational attainment | |||
| None | 22 (16.8) | 16 (17.8) | 26 (20.5) |
| Primary | 47 (35.9) | 30 (33.3) | 48 (37.8) |
| Secondary | 34 (25.9) | 25 (27.8) | 48 (37.8) |
| Tertiary | 19 (14.5) | 12 (13.3) | 21 (16.5) |
| Number of children who slept under a bed net the previous night (%) | 41 (31.3) | 33 (36.7) | 52 (40.9) |
| Number of children who took an antimalarial within 2 weeks (%) | 13 (9.9) | 9 (10.0) | 18 (14.2) |
| Number of children who reported seeing bloody urine (%) | 35 (26.7) | 8 (8.9) | 23 (18.1) |
| Number of children who reported seeing bloody stools (%) | 9 (6.9) | 5 (5.6) | 12 (9.4) |
| Number of children who swam in a pond or stagnant body of water (%) | 33 (25.2) | 20 (22.2) | 52 (40.9) |
SD=standard deviation.
Distribution of malaria parasitaemia and moderate anaemia in 348 class three schoolchildren in KNDs, Ghana, in June 2011
| Primary school (number of class three children examined) | Number with malaria parasitaemia, percentage (95% CI) | Number moderately anaemic, percentage (95% CI) |
|---|---|---|
| Naaga (61) | 13, 21.3 (13.7–35.5) | 21, 34.4 (22.4–46.5) |
| Kayoro (70) | 15, 21.4 (14.1–34.4) | 10, 14.3 (6.0–22.6) |
| Katiu (40) | 2, 5.0 (0.8–15.8) | 10, 25.0 (11.4–38.6) |
| Biu (50) | 18, 36.0 (28.1–55.9) | 14, 28.0 (15.4–40.6) |
| Akurugu Daboo (74) | 21, 28.4 (19.3–40.3) | 16, 21.6 (12.1–31.1) |
| Nania (53) | 21, 39.6 (28.1–54.9) | 19, 35.8 (22.8–48.9) |
Effects of interventions on malaria parasitaemia and anaemia in class three schoolchildren in KNDs, Ghana, by study arm
| Variable | Arm 1 ( | Arm 2 ( | Arm 3 ( |
|---|---|---|---|
| Prevalence of malaria parasitaemia | |||
| Before interventions | 24.2, (2.5) | 26.7, (4.1) | 34.7, (3.4) |
| After interventions | 9.0, (1,4) | 10.9, (2.5) | 31.6, (1.7) |
| | 0.001 | 0.001 | 0.148 |
| Malaria parasite density (geometric mean) per 800 WBCs, (SD) | |||
| Before intervention | 346, (38) | 121, (76) | 535, (136) |
| After intervention | 212, (24) | 114, (32) | 368, (21) |
| | 0.531 | 0.741 | 0.350 |
| Mean Hb (g/dl), (SD) | |||
| Before interventions | 11.7, (2.5) | 11.7, (1.2) | 11.6, (1.1) |
| After interventions | 11.8, (1.6) | 11.6, (1.1) | 11.6, (1.2) |
| | 0.745 | 0.631 | 0.701 |
| Prevalence of anaemia, (95% CI) | |||
| Before interventions | 19.8, (16.0–29.2) | 26.7, (13.3–31.0) | 28.3, (6.1–43.2) |
| After interventions | 12.2, (8.3–14.7) | 21.1, (15.4–28.5) | 18.1, (15.8–27.6) |
| | 0.073 | 0.151 | 0.049 |
WBCs=white blood cells.
Impact of interventions on code transmission test (CTT) scores in class three schoolchildren in KNDs, Ghana, 2011 and 2012
| Study arm | Variable | Mean CTT score before interventions in June 2011 (95% CI) | Mean CTT score after interventions in June 2012 (95% CI) | |
|---|---|---|---|---|
| Arm 1 (AL+ALB) | Boys | 3.14 (2.95–3.33) | 3.47 (3.26–3.69) | 0.02 |
| Girls | 3.23 (3.10–3.36) | 3.63 (3.46–3.80) | 0.01 | |
| Total | 3.18 (2.94–3.38) | 3.55 (3.20–3.91) | 0.01 | |
| 6–9 years | 3.24 (3.06–3.42) | 3.58 (3.26–3.91) | 0.06 | |
| 10–12 years | 3.23 (3.08–3.37) | 3.58 (3.38–3.77) | 0.01 | |
| 13–15 years | 3.14 (2.89–3.38) | 3.54 (3.29–3.78) | 0.01 | |
| Arm 2 (AL+ALB+PZQ) | Boys | 2.83 (2.63–3.02) | 3.49 (3.28–3.69) | 0.01 |
| Girls | 2.84 (2.58–3.10) | 3.64 (3.44–3.84) | 0.01 | |
| Total | 2.83 (2.52–3.14) | 3.56 (3.25–3.86) | 0.01 | |
| 6–9 years | 2.66 (2.31–2.99) | 3.44 (3.19–3.69) | 0.01 | |
| 10–12 years | 2.87 (2.68–3.06) | 3.60 (3.41–3.79) | 0.01 | |
| 13–15 years | 3.07 (2.74–3.39) | 3.56 (2.99–4.11) | 0.11 | |
| Arm 3 (AL+PZQ) | Boys | 3.08 (2.92–3.25) | 3.14 (2.92–3.37) | 0.67 |
| Girls | 2.82 (2.61–3.03) | 3.13 (2.81–3.44) | 0.11 | |
| Total | 2.95 (2.58–3.29) | 3.13 (2.75–3.48) | 0.09 | |
| 6–9 years | 3.05 (2.83–3.28) | 3.15 (2.79–3.46) | 0.72 | |
| 10–12 years | 2.91 (2.73–3.08) | 3.18 (2.94–3.42) | 0.07 | |
| 13–15 years | 3.07 (2.62–3.51) | 2.83 (2.04–3.62) | 0.54 |
AL=Artemether-lumefantrine; ALB=albendazole; PZQ=praziquantel; CI=confidence interval.
Impact of interventions on mean recall test scores in class three schoolchildren in KNDs, Ghana, 2011 and 2012
| Study arm | Variable | Mean recall test score before interventions in June 2011 (95% CI) | Mean recall test score after interventions in June 2012 (95% CI) | |
|---|---|---|---|---|
| Arm 1 (AL+ALB) | Boys | 2.05 (1.89–2.21) | 2.71 (2.54–2.87) | 0.01 |
| Girls | 2.09 (1.98–2.21) | 2.08 (2.66–2.91) | 0.01 | |
| Total | 2.07 (1.82–2.34) | 2.49 (2.32–2.96) | 0.01 | |
| 6–9 years | 2.28 (2.03–2.53) | 2.67 (2.35–2.97) | 0.05 | |
| 10–12 years | 1.98 (1.85–2.12) | 2.78 (2.64–2.91) | 0.01 | |
| 13–15 years | 2.09 (1.95–2.24) | 2.75 (2.58–2.92) | 0.01 | |
| Arm 2 (AL+ALB+PZQ) | Boys | 1.89 (1.73–2.04) | 2.54 (2.35–2.73) | 0.01 |
| Girls | 1.92 (1.69–2.14) | 2.76 (2.58–2.94) | 0.01 | |
| Total | 1.91 (1.63–2.16) | 2.65 (2.31–2.97) | 0.01 | |
| 6–9 years | 2.14 (1.94–2.33) | 2.67 (2.43–2.91) | 0.01 | |
| 10–12 years | 1.80 (1.62–1.98) | 2.54 (2.35–2.74) | 0.01 | |
| 13–15 years | 1.73 (1.40–2.06) | 2.89 (2.63–3.15) | 0.01 | |
| Arm 3 (AL+PZQ) | Boys | 1.98 (1.83–2.14) | 2.38 (2.19–2.56) | 0.01 |
| Girls | 1.86 (1.71–2.01) | 2.31 (2.09–2.53) | 0.01 | |
| Total | 1.92 (1.68–2.18) | 2.35 (2.04–2.61) | 0.01 | |
| 6–9 years | 2.05 (1.83–2.28) | 2.38 (2.10–2.65) | 0.07 | |
| 10–12 years | 1.83 (1.69–1.96) | 2.39 (2.22–2.55) | 0.01 | |
| 13–15 years | 2.13 (1.78–2.45) | 2.00 (1.34–2.66) | 0.67 |
AL=Artemether-lumefantrine; ALB=albendazole; PZQ=praziquantel; CI=confidence interval.